
    
      This is multicenter, randomized, double-blind, double-dummy, placebo-controlled, three-way
      cross-over, incomplete block design study to evaluation of 5 doses of GSK573719 administered
      once-daily and 3 doses of GSK573719 administered twice-daily over 14 days in subjects with
      COPD and will include tiotropium as an open-label active control. The pharmacokinetic profile
      of GSK573719 will also be evaluated.
    
  